Sonescence is a privately held, pre-commercial bio-medical research company focused on the development and commercialization of a highly effective new drug delivery technology called Ultrasonic Drug Disperson (UDD). Our current research is focused on a therapy for chronic wounds and serious skin and skin structure infections (SSSIs), including those caused by antibiotic-resistant organisms such as Methicillin-resistant Staphylococcus aureus (MRSA).
A whole new way to deliver drugs to the target location, independent of blood supply
Seeking cures for chronic wounds and skin & skin structure infections - Currently in Phase 2
A Global Health Crisis
Our current research seeks to overcome antibiotic-resistant bacteria at the source